Rentschler Biophrama appoints Robert Panting as General Manager

UNITED KINGDOM – Rentschler Biopharma, a global CDMO for biopharmaceuticals, has appointed Dr. Robert Panting has been appointed General Manager of Rentschler ATMP Ltd.’s center of excellence in Stevenage, UK, Europe’s largest cell and gene therapy hub.

Rentschler ATMP Ltd.’s center of excellence is Europe’s largest cell and gene therapy hub. It was established to fill a capacity and support gap for early-stage innovators in cell and gene therapy. Dr. Panting will oversee all operations at the site in this capacity.

Dr. Panting previously worked for Fujifilm Diosynth Biotechnologies for ten years, where he held positions of increasing responsibility in project management, customer management, and business planning.

He most recently served as Vice President for Program Management and Sales & Operations Planning, where he was responsible for driving client project delivery and overseeing short- and long-term planning for the company’s UK operations.

He was also in charge of a number of infrastructure and major organizational projects. Prior to that, he was Senior Director of Programs, where he was in charge of customer projects in the United Kingdom. He was also in charge of project and portfolio management implementation, including the onboarding of a newly acquired site’s portfolio management team.

I am delighted to welcome Dr. Robert Panting to the Rentschler team. With his great experience running complex operations and setting up the structures needed for a new site, he is the ideal choice to manage our cell and gene therapy facility,” said Dr. Frank Mathias, CEO of Rentschler Biopharma.

We are excited by the great progress we have made since launching our plans in the UK earlier this year and look forward to establishing this facility for the state-of-the-art manufacturing of viral vectors for clinical supply. Dr. Panting’s leadership will be a critical aspect of driving this project to be client-ready for cGMP manufacturing.”

Center of Excellence (COE) to address the gap in capacity and support for early-stage innovators in cell and gene therapy.

The company intends to collaborate with entrepreneurial players at this new Center of Excellence to help them turn their ideas into real products that have the potential to treat and even cure patients with serious and life-threatening diseases.

Would you like to get regular updates of such news articles? Subscribe to our HealthCare Africa News, email newsletters, which provide the latest news insights from Africa and the World’s health, pharma and biotech industry. SUBSCRIBE HERE

Related posts

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.